Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95571
UPID:
ETHE1_HUMAN
Alternative names:
Ethylmalonic encephalopathy protein 1; Hepatoma subtracted clone one protein; Sulfur dioxygenase ETHE1
Alternative UPACC:
O95571; Q96HR0; Q9H001
Background:
Persulfide dioxygenase ETHE1, mitochondrial, also known as Ethylmalonic encephalopathy protein 1, plays a crucial role in hydrogen sulfide catabolism within the mitochondrial matrix. It is pivotal in metabolic homeostasis, preventing toxic levels of hydrogen sulfide by catalyzing its oxidation. This protein also interacts with cellular mechanisms to suppress p53-induced apoptosis, showcasing its multifaceted biological significance.
Therapeutic significance:
ETHE1's dysfunction is directly linked to Ethylmalonic encephalopathy, a fatal autosomal recessive disorder marked by neurodevelopmental challenges and metabolic anomalies. Understanding the role of Persulfide dioxygenase ETHE1 could open doors to potential therapeutic strategies, offering hope for targeted interventions in metabolic and neurodevelopmental disorders.